Neuronal acetylcholine receptor subunit beta 2 (CHRNB2) (CHRNB2)

The Neuronal acetylcholine receptor subunit beta 2 (CHRNB2) is a critical protein component of the pentameric nicotinic acetylcholine receptor (nAChR) complex, most frequently pairing with the alpha 4 subunit to form the predominant high-affinity nAChR subtype in the mammalian brain [1, 2]. As a ligand-gated ion channel, it facilitates fast excitatory neurotransmission by allowing the passage of sodium, potassium, and calcium ions upon binding with the neurotransmitter acetylcholine or exogenous nicotine [2, 3]. This subunit is vital for the modulation of various neurotransmitter systems, particularly the release of dopamine in the mesolimbic pathway, which is central to the reinforcing effects of nicotine and the development of addiction [4, 5]. Mutations in the CHRNB2 gene are specifically linked to autosomal dominant sleep-related hypermotor epilepsy (ADSHE), a condition characterized by frequent, brief seizures during sleep [6]. Due to its widespread involvement in cognitive and reward processes, the beta 2 subunit serves as a primary therapeutic target for smoking cessation drugs like varenicline and is actively researched for its potential in treating neurodegenerative and psychiatric disorders [7, 8].

Other names

Nicotinic acetylcholine receptor subunit beta 2nAChR beta 2Cholinergic receptor nicotinic beta 2 subunitEFNL3

Partial agonism or full agonism to stimulate neurotransmitter release and modulate reward pathways; antagonism to block the effects of exogenous nicotine; positive allosteric modulation to enhance endogenous cholinergic signaling.